Key facts
- Somnair’s last known valuation is $14.8M (Jul 2025).
- It has raised $4.3M across 1 recorded rounds; the latest was Seed Round ($4.3M) in Jun 2025.
- Notable investors include Texas Medical Center, VentureWell, J2 Ventures, Jumpspace Ventures, Nexus NeuroTech Ventures — 16 tracked in total.
- Somnair has filed 1 Form D with the SEC, most recently Jul 2025 ($4.3M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Somnair
Funding rounds
1 roundsAbout Somnair
Developer of a non-invasive neurostimulation device intended for the treatment of obstructive sleep apnea. The company's platform delivers therapy that targets the root neurological causes of airway obstruction without surgical intervention, is deployable in a home setting, enabling healthcare providers to access a potentially more accessible, patient-friendly alternative to traditional continuous positive airway pressure or implant-based therapies.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2022
- Employees
- 6
- Website
- somnairsleep.com/
- Ownership
- Privately Held (backing)
Somnair doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Somnair shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Somnair in its N-PORT filings yet. We sweep new filings monthly.